89288-25-5

Basic information

• Product Name: BAY-m 4798
• CAS NO: 89288-25-5
• Molecular Weight: 342.308
• Mol File: 89288-25-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: BAY-m 4798(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-m 4798(89288-25-5)
• EPA Substance Registry System: BAY-m 4798(89288-25-5)

Safety Data

• Hazardous Substances Data: 89288-25-5(Hazardous Substances Data)

Upstream product

• 89267-47-0 ethyl-2-methyl-4-(3-nitrophenyl)-5-oxo-1,4,5,7-tetrahydrofuro<3,4-b>-3-pyridinecarboxylate 
• 62760-94-5 diethyl-2-acetoxymethyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 99-61-6 3-nitro-benzaldehyde 
• 35594-15-1 ethyl 4-acetoxyacetoacetate 
• 41867-20-3 ethyl (E)-3-aminobut-2-enoate 
• 39562-70-4 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid ethyl methyl ester 

Downstream Products

• 89267-43-6 C₁₇H₁₆N₂O₇ 

Relevant articles and documents

Synthesis method of nitrendipine metabolite

The invention discloses a synthesis method of nitrendipine metabolite. The method takes 4-(benzyloxy)-3-ethyl oxo-butyrate and 3-hydroxypropionitrile as starting raw materials to synthesize the nitrendipine metabolite through 6-step reaction. A lot of experiments are carried out to screen optimal preparation steps and reaction conditions; a whole technology is reasonably designed and strong in operability; the chemical purity of the nitrendipine metabolite prepared by the synthesis method can reach 99 percent or more and the yield is high. The nitrendipine metabolite prepared by the synthesismethod provides a standard product for metabolic mechanism researches of a nitrendipine medicine and can be used for exploring a metabolic process of the medicine in organisms; the nitrendipine metabolite has a relatively good potential hypertension-resisting effect and has extremely application and research value in clinical pharmacokinetics researches.

Biotransformation of nitrendipine in rat, dog, and mouse

14C-Labelled Nitrendipine (Bay e 5009; Baypress, Bayotensin; CAS 39562-70-4) was administered by the oral and intraduodenal route to rats, dogs, and mice (oral dosing only) to elucidate the biotransformation pathways in these three species. The drug was extensively metabolized: 20 biotransformation products were identified by comparison with synthetic reference compounds using two-dimensional TLC, HPLC, GC/radio-GC, combined GC/MS (EI-, CI-mode), FAB-MS, and 1H-NMR-spectroscopy. The metabolites identified accounted for approx. 72 to 73% of the dose administered in rats and dogs (bile and urine) and 48 to 56% in male and female mice (urine only). Based on the structures identified the following biotransformation reactions occurred: Dehydrogenation of the 1,4-dihydropyridine (primary metabolic step), oxidative ester cleavage as further basic biotransformation reaction (also at the dihydropyridine state), hydroxylation of the methyl groups in 2- or 6-position as separated and important metabolic reaction (at the dihydropyridine as well as pyridine state), reduction of the aromatic nitro group (important only in mice) and subsequent acetylation (dog only), and glucuronidation as phase II reaction forming ether and ester type glucuronides.